Completed clinical trials

Retina Vitreous Associates of Florida

Completed Clinical Studies

CR39521 STAIRWAY Study

Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration

GX30191 OMASPECT Study

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

GX28228 LADDER Study

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Age-Related Macular Degeneration

GX29176 CHROMA Study

A Phase 3 Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

M-01-15-004 PALADIN Study

A Phase 4, Safety Study of IOP Signals in Patients Treated with ILUVIEN (Fluocinolone Acetonide Intravitreal Implant)

BP30099 BOULEVARD Study

A Multiple-Center, Randomized, Double-Masked Study to Investigate the Efficacy of RG7716 Administered Intravitreally in Patients with Diabetic Macular Edema

BP29647 AVENUE Study

A Multiple-Center, Randomized, Double-Masked Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

RTH-258-C001 HAWK Study

A Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy of RTH258 versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration

190342-038 BEACON Study

A Phase 2 Study Assessing the Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular

Degeneration

150998-005 CEDAR Study

A Phase 3 Study Assessing the Safety and Efficacy Study of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration

GX29185 SPECTRI Study

A Phase 3 Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

OPH1004

A Phase III Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination with Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

TG-MV-018 Ocriplasmin Research to Better Inform Treatment

Phase 4 Trial Evaluating The Clinical Outcomes And Safety In Patients Receiving Jetrea® for the Treatment Of Symptomatic Vitreomacular Adhesion

This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider.

IF YOU BELIEVE YOU HAVE A MEDICAL EMERGENCY, YOU SHOULD IMMEDIATELY CALL 911 OR YOUR PHYSICIAN. If you believe you have any other health problem, or if you have any questions regarding your health or a medical condition, you should promptly consult your physician or other healthcare provider. Never disregard medical or professional advice, or delay seeking it, because of something you read on this site or a linked website. Never rely on information on this website in place of seeking professional medical advice. You should also ask your physician or other healthcare provider to assist you in interpreting any information in this Site or in the linked websites, or in applying the information to your individual case.

Medical information changes constantly. Therefore the information on this Site or on the linked websites should not be considered current, complete or exhaustive, nor should you rely on such information to recommend a course of treatment for you or any other individual. Reliance on any information provided on this Site or any linked websites is solely at your own risk.